Filtered By:
Drug: Allopurinol
Countries: Austria Health
This page shows you your search results in order of date.
Order by Relevance | Date
Total 2 results found since Jan 2013.
Cardiovascular risk and mortality in patients with hyperuricemia treated with febuxostat or allopurinol: a retrospective nation-wide cohort study in Austria 2014 –2017
AbstractPatients with hyperuricemia and gout are at an increased risk for cardiovascular (CV) disease. Inhibition of the xanthine oxidase with allopurinol or febuxostat have become the mainstay for urate lowering therapy. However, it has been suggested that febuxostat increases the risk for CV mortality as compared to allopurinol. The aim of this retrospective cohort study was to assess the CV risk among patients with febuxostat or allopurinol therapy. Patients who initiated urate lowering therapy with febuxostat or allopurinol between 2014 and 2017 were selected from the drug reimbursement database of the Austrian health ...
Source: Rheumatology International - May 19, 2022 Category: Rheumatology Source Type: research
